4//SEC Filing
Valeant Pharmaceuticals International, Inc. 4
Accession 0000885590-15-000028
$BHCCIK 0000885590operating
Filed
Apr 27, 8:00 PM ET
Accepted
Apr 28, 4:24 PM ET
Size
8.1 KB
Accession
0000885590-15-000028
Insider Transaction Report
Form 4
Mirovsky Pavel
President of Valeant Europe
Transactions
- Exercise/Conversion
Common Stock, no par value
2015-04-24+2,500→ 36,675 total - Exercise/Conversion
Restricted Share Units
2015-04-24−2,500→ 7,500 total→ Common Stock (7,500 underlying)
Footnotes (3)
- [F1]Each performance-based Restricted Share Unit ("PSU") represents a contingent right to receive between zero and three common shares, no par value ("Common Shares"), of Valeant Pharmaceuticals International, Inc. ("Valeant"), subject to performance based vesting criteria. See note (2).
- [F2]This represents the number of units vested on the PSUs that were previously reported on the original Form 4. The initial grant was reported to vest based on total shareholder return ("TSR") between a price of $54.15 starting on May 15, 2012 and the average stock price for the 20 trading days starting on each measurement dates: 25% on February 15, 2015, 50% on May 15, 2015 and 25% on August 15, 2015. Unit vesting is contingent on TSR performance between 15% and 45% into between one and three shares of common stock, respectively, with early vesting possible at higher TSR levels. The PSU award may still payout 7,500 units.
- [F3]Represents the maximum number of Common Shares that may be issued under the PSU award.
Documents
Issuer
Valeant Pharmaceuticals International, Inc.
CIK 0000885590
Entity typeoperating
IncorporatedNJ
Related Parties
1- filerCIK 0000885590
Filing Metadata
- Form type
- 4
- Filed
- Apr 27, 8:00 PM ET
- Accepted
- Apr 28, 4:24 PM ET
- Size
- 8.1 KB